Lipoprotein metabolism mediates the association of MTP polymorphism with β-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis

Journal of Nutritional Biochemistry

Volumn 21, Issue 9, 2010, Pages 834-840

  Musso, Giovanni ^a   Gambino, Roberto ^b   Cassader, Maurizio ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

cell; ApoB48; Disposition index; Microsomal triglyceride transfer protein; Oxidized LDL; Postprandial; VLDL subfractions

Indexed keywords

ADIPOCYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DIET; DISEASE SEVERITY; FAT INTAKE; FEMALE; GENOTYPE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPOPROTEIN METABOLISM; MALE; NONALCOHOLIC FATTY LIVER; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; POSTPRANDIAL STATE; PROTEIN POLYMORPHISM;

ADULT; CARRIER PROTEINS; CHOLESTEROL, HDL; DIABETES MELLITUS; DIETARY FATS; FATTY LIVER; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN-SECRETING CELLS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RISK;

EID: 77955845052     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.06.007     Document Type: Article

References (30)

1. Sattar N., Scherbakova O., Ford I., O'Reilly D.S., Stanley A., Forrest E. Elevated alanine aminotransferase predicts new-onset Type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004, 53:2855-2860.
2. Shibata M., Kihara Y., Taguchi M., Tashiro M., Otsuki M. Nonalcoholic fatty liver disease is a risk factor for Type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30:2940-2944.
3. Tushuizen M.E., Bunck M.C., Pouwels P.J., van Waesberghe J.H., Diamant M., Heine R.J. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006, 26:1015-1017.
4. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008, 14:72-81.
5. Robertson R.P., Harmon J., Tran P.O.T., Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in Type 2 diabetes. Diabetes 2004, 53:S119-S124.
6. Ustundag Y., Ozer I.O., Yenidunia S. Oxidized low density lipoprotein in liver tissue samples of our NASH patients, alcoholic and chronic viral hepatitis cases. Gastroenterology 2002, 57:203.
7. Hoogeveen R.C., Ballantyne C.M., Bang H., Heiss G., Duncan B.B., Folsom A.R. Circulating oxidised low-density lipoprotein and intercellular adhesion molecule-1 and risk of Type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Diabetologia 2007, 50:36-42.
8. Roehrich M.E., Mooser V., Lenain V., Herz J., Nimpf J., Azhar S. Insulin-secreting β-Cell dysfunction induced by human lipoproteins. J Biol Chem 2003, 278:18368-18375.
9. Abderrhamani A., Niederhauser G., Favre D., Abdelli S., Ferdaoussi M., Yang J.Y. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta-cells. Diabetologia 2007, 50:1304-1314.
10. Arsov T., Carter C.Z., Nolan C.J., Petrovsky N., Goodnow C.C., Teoh N.C. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Comm 2006, 342:1152-1159.
11. Namikawa C., Shu-Ping Z., Vyselaar J.R., Nozaki Y., Nemoto Y. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 2004, 40:781-786.
12. Gambino R., Cassader M., Pagano G., Durazzo M., Musso G. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology 2007, 45:1097-1107.
13. Karpe F., Lundahl B., Ehrenborg E., Eriksson P., Hamsten A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol 1998, 18:756-761.
14. Rubin D., Helwig U., Pfeuffer M., Schreiber S., Boeing H., Fisher E. A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with Type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet 2006, 51:567-574.
15. Niswender K.D., Magnuson M.A. Obesity and the β cell: lessons from leptin. J Clin Invest 2007, 117:2753-2756.
16. Ravikumar B., Carey P.E., Snaar J.E., Deelchand D.K., Cook D.B., Neely R.D. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and Type 2 diabetes. Am J Physiol Endocrinol Metab 2005, 288:E789-E797.
17. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
18. Prati D., Taioli E., Zanella A., Della Torre E., Butelli S., Del Vecchio E. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-9.
19. Chang Y., Ryu S., Sung E., Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict non-alcoholic fatty liver disease. Clin Chem 2007, 53:686-692.
20. Pisani P., Faggiano F., Krogh V., Palli D., Vineis P., Berrino F. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centers. Int J Epidemiol 1997, 26(Suppl 1):S152-S160.
21. Carnovale E., Marletta Food composition table. Istituto Nazionale della Nutrizione 1997, EDRA, Milano.
22. Pacini G., Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003, 17:305-322.
23. Abdul-Ghani M.A., Williams K., DeFronzo R.A., Stern M. What is the best predictor of future type 2 diabetes?. Diabetes Care 2007, 30:1544-1548.
24. Tura A., Kautzky-Willer A., Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 2006, 72:298-301.
25. Cobelli C., Toffolo G.M., Man C.D., Campioni M., Denti P., Caumo A. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007, 293:E1-E15.
26. Damcott C.M., Pollin T.I., Reinhart L.J., Ott S.H., Shen H., Silver K.D. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with Type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006, 55:2654-2659.
27. Vittinghoff E., Shiboski S.C., McCullouch C.E., Glidden D.V. Regression methods in biostatistics: linear, logistic, survival and repeated measures models 2005, Springer Science+Business Media, Inc; Statistics for Biology and Health, New York (NY).
28. Thabut D., Tazi K.A., Bonnefont-Rousselot D., Aller M., Farges O., Guimont M.C., et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology 2007, 46:1893-1906.
29. Mathur A., Marine M., Lu D., Swartz-Basile D.A., Saxena R., Zyromski N.J. A nonalcoholic fatty pancreas disease. HPB (Oxford) 2007, 9:312-318.
30. Meier J.J., Gethmann A., Götze O., Gallwitz B., Holst J.J., Schmidt W.E. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006, 49:452-458.